Prevalence of Epstein–Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer
Table 1
Clinical characteristics of Tibetan patients with gastric cancer.
Variable
EBV infection
MMR expression
EBV-negative ()
EBV-positive ()
value
pMMR ()
dMMR ()
value
Median age (range)
51 (23-74)
54 (36-62)
0.834
51 (23-72)
59 (54-74)
0.078
Sex—no. (%)
0.092
Male
78 (71.6)
5 (45.5)
76 (69.7)
4 (66.7)
Female
31 (28.4)
6 (54.5)
33 (30.3)
2 (66.7)
Histological type—no. (%)
0.743
0.750
Adenocarcinoma
85 (78.0)
9 (81.8)
84 (77.1)
6 (100)
Mucinous adenocarcinoma
4 (3.7)
0 (0)
4 (3.7)
0 (0)
Signet-ring cell carcinoma
4 (3.7)
1 (9.1)
5 (4.6)
0 (0)
Mixed
16 (14.7)
1 (9.1)
16 (14.7)
0 (0)
Location— no. (%)
0.225
0.454
Cardia/fundus
8 (7.3)
0 (0)
8 (7.3)
0 (0)
Gastric body
23 (21.1)
5 (45.5)
28 (25.7)
0 (0)
Pylorus
78 (71.6)
6 (54.5)
73 (67.0)
6 (100)
Tumor size—no. (%)
1.000
0.224
<5
44 (40.4)
4 (36.4)
43 (39.4)
4 (66.7)
≥5
65 (59.6)
7 (63.6)
66 (60.6)
2 (33.3)
Grade—no. (%)
0.025
0.815
Well differentiation
7 (6.4)
2 (18.2)
9 (8.3)
0 (0)
Middle differentiation
49 (45.0)
1 (9.1)
44 (40.4)
2 (33.3)
Poor differentiation
53 (48.6)
8 (72.7)
56 (51.4)
4 (66.7)
T stage
0.863
1.000
T1
2 (1.8)
0 (0)
2 (1.8)
0 (0)
T2
19 (17.4)
1 (9.1)
19 (17.4)
1 (16.7)
T3
58 (53.2)
6 (54.5)
59 (54.1)
3 (50.0)
T4
30 (27.5)
4 (36.4)
29 (26.6)
2 (33.3)
N stage
0.792
0.046
N0
27 (24.8)
3 (27.3)
28 (25.7)
1 (16.7)
N1
22 (20.2)
1 (9.1)
19 (17.4)
4 (66.7)
N2
20 (18.3)
3 (27.3)
21 (19.3)
0 (0)
N3
40 (36.7)
4 (36.4)
41 (37.6)
1 (16.7)
TNM stage (AJCC 8th)
0.897
0.843
I
12 (11.0)
1 (9.1)
12 (11.0)
1 (16.7)
II
38 (34.9)
3 (27.3)
37 (33.9)
2 (33.3)
III
59 (54.1)
7 (63.6)
60 (55.0)
3 (50.0)
Vascular invasion
0.458
1.000
Yes
84 (77.1)
7 (63.6)
82 (75.2)
5 (83.3)
No
25 (22.9)
4 (36.4)
27 (24.8)
1 (16.7)
Note: Five of 120 patients could not be evaluated for MMR status.
